Bronchitis is the inflammation of the bronchial tubes, which transport air to and from the lungs. There are two categories for it, namely, acute and chronic. Usually caused by viral infections, acute bronchitis lasts a few weeks and manifests as symptoms including wheezing, mucus production, and a persistent cough. Chronic bronchitis is a chronic illness that is frequently associated with smoking. A cough that lasts at least three months annually for two years in a row is the hallmark of the condition. Both types may cause breathing problems and, in extreme cases, necessitate medical care. The bronchitis pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the bronchitis treatment market include Incyte Biosciences Japan GK, Syndax Pharmaceuticals and SCM Lifescience Co., Ltd.
Leading drugs currently under the pipeline include axatilimab and SCM-CGH, among others.
The increasing cases of bronchitis and the rising technological advancements are poised to positively influence the bronchitis pipeline landscape.
The Bronchitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bronchitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bronchitis. The bronchitis report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The bronchitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with bronchitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bronchitis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The pathophysiology of bronchitis include inflammation of the bronchial tubes that causes mucosal thickening and increased mucus production. Viral infections are usually the cause of this inflammation in acute bronchitis, which damages epithelial cells and obstructs the airway because of mucus buildup. Chronic bronchitis, which is frequently linked to smoking, is characterized by goblet cells' excessive mucus production and ongoing inflammation, which restricts airways and causes repeated coughing. Both types may lead to weakened mucociliary systems and heightened vulnerability to infections.
Treatment for bronchitis focuses on relieving symptoms and improving lung function. For acute bronchitis, rest, hydration, and over-the-counter pain relievers like ibuprofen are recommended. Cough suppressants may be used if mucus is not present. In cases of chronic bronchitis, treatment includes bronchodilators to open airways, corticosteroids to reduce inflammation, and lifestyle changes such as quitting smoking. Pulmonary rehabilitation and oxygen therapy may also be beneficial. Antibiotics are only prescribed if a bacterial infection is suspected.
Globally, the prevalence of bronchitis varies. In the United States, 3.6% of adults had the condition, and as of 2018, there were roughly 9 million instances of chronic bronchitis. Women are more likely than men to have the illness, and older adults, especially those over 65, are more likely to have it. Prevalence rates in the general population vary from 3.4% to 22% globally, with greater rates among those who suffer from chronic obstructive pulmonary disease (COPD). It is a major cause of respiratory illness and mortality.
This section of the report covers the analysis of bronchitis drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of bronchitis drugs undergoing clinical development.
The drug molecule categories covered under bronchitis pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The bronchitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Bronchitis.
The EMR report for the Bronchitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bronchitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Bronchitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bronchitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bronchitis drug candidates:
Axatilimab, developed by Incyte Biosciences Japan GK, is a humanized monoclonal antibody targeting the CSF-1 receptor (CSF-1R). It is currently in Phase 3 clinical trials for the treatment of chronic graft-versus-host disease (cGVHD), a complication following stem cell transplantation. Axatilimab works by inhibiting CSF-1R, reducing the activity of monocytes and macrophages, which drive inflammation and tissue damage in chronic graft versus host disease (cGvHD). The drug has shown promising efficacy and safety, offering potential therapeutic benefits for patients with cGVHD.
SCM-CGH, developed by SCM Lifescience Co., Ltd., is an investigational stem cell therapy currently in Phase 2 clinical trials for the treatment of chronic graft-versus-host disease (cGVHD). It utilizes high-purity mesenchymal stem cells (MSCs) with potent immunomodulatory and anti-inflammatory properties. The therapy aims to reduce immune-mediated tissue damage by regulating T-cell activity and suppressing inflammatory responses. SCM-CGH has shown potential in improving symptoms and enhancing the quality of life for cGVHD patients, offering a promising therapeutic option.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Bronchitis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bronchitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bronchitis collaborations market trends, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share